Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000-2018.
Africa
Demographics
Geostatistics
HIV
HIV prevalence
Mapping
Spatial statistics
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
19 12 2022
19 12 2022
Historique:
received:
26
04
2022
accepted:
26
10
2022
entrez:
18
12
2022
pubmed:
19
12
2022
medline:
21
12
2022
Statut:
epublish
Résumé
Human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS) is still among the leading causes of disease burden and mortality in sub-Saharan Africa (SSA), and the world is not on track to meet targets set for ending the epidemic by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the United Nations Sustainable Development Goals (SDGs). Precise HIV burden information is critical for effective geographic and epidemiological targeting of prevention and treatment interventions. Age- and sex-specific HIV prevalence estimates are widely available at the national level, and region-wide local estimates were recently published for adults overall. We add further dimensionality to previous analyses by estimating HIV prevalence at local scales, stratified into sex-specific 5-year age groups for adults ages 15-59 years across SSA. We analyzed data from 91 seroprevalence surveys and sentinel surveillance among antenatal care clinic (ANC) attendees using model-based geostatistical methods to produce estimates of HIV prevalence across 43 countries in SSA, from years 2000 to 2018, at a 5 × 5-km resolution and presented among second administrative level (typically districts or counties) units. We found substantial variation in HIV prevalence across localities, ages, and sexes that have been masked in earlier analyses. Within-country variation in prevalence in 2018 was a median 3.5 times greater across ages and sexes, compared to for all adults combined. We note large within-district prevalence differences between age groups: for men, 50% of districts displayed at least a 14-fold difference between age groups with the highest and lowest prevalence, and at least a 9-fold difference for women. Prevalence trends also varied over time; between 2000 and 2018, 70% of all districts saw a reduction in prevalence greater than five percentage points in at least one sex and age group. Meanwhile, over 30% of all districts saw at least a five percentage point prevalence increase in one or more sex and age group. As the HIV epidemic persists and evolves in SSA, geographic and demographic shifts in prevention and treatment efforts are necessary. These estimates offer epidemiologically informative detail to better guide more targeted interventions, vital for combating HIV in SSA.
Sections du résumé
BACKGROUND
Human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS) is still among the leading causes of disease burden and mortality in sub-Saharan Africa (SSA), and the world is not on track to meet targets set for ending the epidemic by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the United Nations Sustainable Development Goals (SDGs). Precise HIV burden information is critical for effective geographic and epidemiological targeting of prevention and treatment interventions. Age- and sex-specific HIV prevalence estimates are widely available at the national level, and region-wide local estimates were recently published for adults overall. We add further dimensionality to previous analyses by estimating HIV prevalence at local scales, stratified into sex-specific 5-year age groups for adults ages 15-59 years across SSA.
METHODS
We analyzed data from 91 seroprevalence surveys and sentinel surveillance among antenatal care clinic (ANC) attendees using model-based geostatistical methods to produce estimates of HIV prevalence across 43 countries in SSA, from years 2000 to 2018, at a 5 × 5-km resolution and presented among second administrative level (typically districts or counties) units.
RESULTS
We found substantial variation in HIV prevalence across localities, ages, and sexes that have been masked in earlier analyses. Within-country variation in prevalence in 2018 was a median 3.5 times greater across ages and sexes, compared to for all adults combined. We note large within-district prevalence differences between age groups: for men, 50% of districts displayed at least a 14-fold difference between age groups with the highest and lowest prevalence, and at least a 9-fold difference for women. Prevalence trends also varied over time; between 2000 and 2018, 70% of all districts saw a reduction in prevalence greater than five percentage points in at least one sex and age group. Meanwhile, over 30% of all districts saw at least a five percentage point prevalence increase in one or more sex and age group.
CONCLUSIONS
As the HIV epidemic persists and evolves in SSA, geographic and demographic shifts in prevention and treatment efforts are necessary. These estimates offer epidemiologically informative detail to better guide more targeted interventions, vital for combating HIV in SSA.
Identifiants
pubmed: 36529768
doi: 10.1186/s12916-022-02639-z
pii: 10.1186/s12916-022-02639-z
pmc: PMC9760541
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
488Subventions
Organisme : FIC NIH HHS
ID : K43 TW010716
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : FIC NIH HHS
ID : K43 TW010704
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIDA NIH HHS
ID : K01 DA051346
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
BMC Public Health. 2016 Nov 3;16(1):1136
pubmed: 27809824
N Engl J Med. 2012 Apr 5;366(14):1270-3
pubmed: 22475591
AIDS. 2012 Jul 31;26 Suppl 1:S19-30
pubmed: 22781175
Lancet HIV. 2020 Sep;7(9):e629-e640
pubmed: 32771089
Public Health Rep. 2010 Jul-Aug;125 Suppl 4:1-5
pubmed: 20629250
J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):76-83
pubmed: 14501798
Nature. 2019 Jun;570(7760):189-193
pubmed: 31092927
PLoS One. 2013 Oct 02;8(10):e76158
pubmed: 24098434
Bull World Health Organ. 2002;80(2):89-96
pubmed: 11953786
Sci Rep. 2017 Aug 22;7(1):9093
pubmed: 28831171
Lancet HIV. 2016 Sep;3(9):e441-e448
pubmed: 27562745
BMC Med. 2018 Feb 9;16(1):22
pubmed: 29422096
Sci Data. 2017 Jan 31;4:170004
pubmed: 28140397
PLoS Med. 2020 Mar 6;17(3):e1003042
pubmed: 32142509
BMJ Glob Health. 2016 Dec 30;1(4):e000125
pubmed: 28588979
AIDS. 2001 Aug 17;15(12):1576-9
pubmed: 11504992
Curr HIV/AIDS Rep. 2019 Feb;16(1):120-128
pubmed: 30707399
AIDS. 2014 Nov;28 Suppl 4:S469-76
pubmed: 25406750
Public Health. 2019 May;170:57-60
pubmed: 30933882
Nature. 2015 Dec 3;528(7580):S77-85
pubmed: 26633769
Lancet Infect Dis. 2016 Dec;16(12):1320-1322
pubmed: 27998582
Lancet. 2020 Oct 17;396(10258):1160-1203
pubmed: 33069325
Soc Sci Med. 2010 Oct;71(8):1428-35
pubmed: 20739108
Int Health. 2016 Jul;8(4):277-85
pubmed: 27008897
Lancet. 2016 Dec 10;388(10062):e19-e23
pubmed: 27371184
Sci Transl Med. 2017 Mar 29;9(383):
pubmed: 28356504
J Gen Intern Med. 2013 Oct;28(10):1294-301
pubmed: 23588668
Sex Transm Infect. 2008 Aug;84 Suppl 1:i17-i23
pubmed: 18647861
Lancet. 2017 Nov 11;390(10108):2171-2182
pubmed: 28958464
PLoS Med. 2012;9(12):e1001351
pubmed: 23226107
Lancet HIV. 2020 May;7(5):e308-e309
pubmed: 32272084
BMC Public Health. 2018 Nov 13;18(1):1254
pubmed: 30424761
Lancet HIV. 2019 Dec;6(12):e831-e859
pubmed: 31439534
J R Soc Interface. 2017 Sep;14(134):
pubmed: 28931634
Nature. 2018 Feb 28;555(7694):48-53
pubmed: 29493588
Lancet Glob Health. 2020 Sep;8(9):e1132-e1141
pubmed: 32673577
Glob Health Action. 2019;12(1):1662685
pubmed: 31510887
PLoS Med. 2019 Jan 18;16(1):e1002729
pubmed: 30657770
Nat Commun. 2019 Dec 2;10(1):5482
pubmed: 31792217
Science. 2013 Feb 22;339(6122):966-71
pubmed: 23430656
AIDS. 2000 Dec 1;14(17):2741-50
pubmed: 11125893
Lancet. 2020 5-11 Sep;396(10252):693-724
pubmed: 32334655
Int J Epidemiol. 2009 Aug;38(4):1008-16
pubmed: 19261659
J Int AIDS Soc. 2019 Jul;22(7):e25364
pubmed: 31353831
PLoS Med. 2017 Aug 8;14(8):e1002374
pubmed: 28792502
AIDS. 2018 May 15;32(8):957-963
pubmed: 29547437
AIDS. 2014 Nov;28 Suppl 4:S497-505
pubmed: 25203158
AIDS. 2016 Jun 1;30(9):1475-9
pubmed: 26950317
Proc Natl Acad Sci U S A. 2021 Jul 13;118(28):
pubmed: 34244424
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25244
pubmed: 30907505
BMC Public Health. 2019 Jan 31;19(1):131
pubmed: 30704445
Lancet. 2018 Jul 28;392(10144):312-358
pubmed: 30032975
Trop Med Int Health. 2017 Dec;22(12):1542-1550
pubmed: 28986949
Lancet. 2014 Jul 19;384(9939):249-56
pubmed: 25042235
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
J Trop Med. 2009;2009:145891
pubmed: 20309417
Int J Equity Health. 2016 Jan 22;15:16
pubmed: 26800682